Edward Tenthoff
Stock Analyst at Piper Sandler
(2.19)
# 2,630
Out of 4,784 analysts
182
Total ratings
37.36%
Success rate
-3.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.51 | +289.94% | 8 | Mar 20, 2025 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $53 → $48 | $11.45 | +319.21% | 6 | Feb 28, 2025 | |
| MESO Mesoblast | Reiterates: Overweight | $15 → $24 | $12.11 | +98.18% | 5 | Feb 7, 2025 | |
| LEGN Legend Biotech | Reiterates: Overweight | $78 | $35.06 | +122.48% | 4 | Dec 30, 2024 | |
| XNCR Xencor | Upgrades: Overweight | $20 → $30 | $11.23 | +167.14% | 4 | Dec 2, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $62 → $45 | $13.82 | +225.62% | 11 | Nov 27, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $296 | $268.46 | +10.26% | 13 | Nov 18, 2024 | |
| MRNA Moderna | Reiterates: Overweight | $115 → $69 | $31.12 | +121.72% | 12 | Nov 18, 2024 | |
| KRON Kronos Bio | Downgrades: Neutral | $6 → $1 | $0.83 | +21.21% | 7 | Nov 14, 2024 | |
| TPST Tempest Therapeutics | Maintains: Overweight | $8 → $5 | $0.77 | +547.58% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $4.29 | +319.58% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $11.50 | +204.35% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $0.74 | +1,392.33% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.87 | +969.52% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.70 | +76.47% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.92 | +226.09% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $5.10 | +213.73% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $36.99 | +183.86% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $0.85 | +606.46% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 | $3.32 | +4,418.07% | 4 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $0.88 | +468.18% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $15 | $3.01 | +398.34% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $29.62 | +89.06% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $55 | $7.59 | +624.64% | 6 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $31 | $1.22 | +2,440.98% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3 | $0.25 | +1,100.00% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $6 | $0.50 | +1,102.40% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $0.72 | +1,148.27% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $19.34 | +127.51% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $8.97 | +312.49% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112,332 → $32,560 | $1.12 | +2,907,042.86% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $589.15 | -39.91% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.28 | +10,446.88% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $492.69 | -34.44% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $36.70 | -1.91% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.27 | +1,868.50% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.54 | +27,672.64% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $1.24 | +4,174.19% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.71 | +194,266.20% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $637.36 | - | 11 | Feb 13, 2017 |
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.51
Upside: +289.94%
Dyne Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $11.45
Upside: +319.21%
Mesoblast
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $12.11
Upside: +98.18%
Legend Biotech
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $35.06
Upside: +122.48%
Xencor
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $11.23
Upside: +167.14%
Arrowhead Pharmaceuticals
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $13.82
Upside: +225.62%
Alnylam Pharmaceuticals
Nov 18, 2024
Reiterates: Overweight
Price Target: $296
Current: $268.46
Upside: +10.26%
Moderna
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $31.12
Upside: +121.72%
Kronos Bio
Nov 14, 2024
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.83
Upside: +21.21%
Tempest Therapeutics
Nov 13, 2024
Maintains: Overweight
Price Target: $8 → $5
Current: $0.77
Upside: +547.58%
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $4.29
Upside: +319.58%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $11.50
Upside: +204.35%
Oct 11, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.74
Upside: +1,392.33%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.87
Upside: +969.52%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.70
Upside: +76.47%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.92
Upside: +226.09%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $5.10
Upside: +213.73%
Jun 17, 2024
Reiterates: Overweight
Price Target: $105
Current: $36.99
Upside: +183.86%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $0.85
Upside: +606.46%
Apr 3, 2024
Maintains: Overweight
Price Target: $150
Current: $3.32
Upside: +4,418.07%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $0.88
Upside: +468.18%
Feb 28, 2024
Maintains: Overweight
Price Target: $13 → $15
Current: $3.01
Upside: +398.34%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $29.62
Upside: +89.06%
Oct 23, 2023
Maintains: Overweight
Price Target: $70 → $55
Current: $7.59
Upside: +624.64%
Aug 14, 2023
Maintains: Overweight
Price Target: $28 → $31
Current: $1.22
Upside: +2,440.98%
Dec 12, 2022
Initiates: Overweight
Price Target: $3
Current: $0.25
Upside: +1,100.00%
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $0.50
Upside: +1,102.40%
Sep 7, 2022
Maintains: Overweight
Price Target: $7 → $9
Current: $0.72
Upside: +1,148.27%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $19.34
Upside: +127.51%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $8.97
Upside: +312.49%
May 13, 2022
Maintains: Overweight
Price Target: $112,332 → $32,560
Current: $1.12
Upside: +2,907,042.86%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $589.15
Upside: -39.91%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.28
Upside: +10,446.88%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $492.69
Upside: -34.44%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $36.70
Upside: -1.91%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.27
Upside: +1,868.50%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.54
Upside: +27,672.64%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $1.24
Upside: +4,174.19%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.71
Upside: +194,266.20%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $637.36
Upside: -